Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Lifted to Hold at StockNews.com

StockNews.com upgraded shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) from a sell rating to a hold rating in a report released on Sunday morning.

A number of other research analysts also recently weighed in on the stock. HC Wainwright restated a buy rating and set a $50.00 price target on shares of Actinium Pharmaceuticals in a report on Monday, April 29th. Maxim Group raised their price objective on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a buy rating in a research note on Tuesday, March 19th. Finally, Cantor Fitzgerald reaffirmed an overweight rating and set a $21.00 target price on shares of Actinium Pharmaceuticals in a research report on Tuesday, April 30th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Actinium Pharmaceuticals has an average rating of Moderate Buy and an average price target of $25.72.

Actinium Pharmaceuticals Price Performance

Actinium Pharmaceuticals stock opened at $8.79 on Friday. Actinium Pharmaceuticals has a 52 week low of $4.00 and a 52 week high of $9.86. The company has a market capitalization of $261.62 million, a P/E ratio of -5.14 and a beta of 0.08.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last announced its quarterly earnings data on Friday, March 29th. The biotechnology company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.21. The business had revenue of $0.08 million for the quarter. Equities analysts forecast that Actinium Pharmaceuticals will post -1.48 EPS for the current year.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Brandywine Global Investment Management LLC acquired a new stake in Actinium Pharmaceuticals in the 3rd quarter worth about $1,033,000. Creative Financial Designs Inc. ADV grew its holdings in shares of Actinium Pharmaceuticals by 19.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 3,175 shares in the last quarter. Finally, Sanders Morris Harris LLC bought a new position in shares of Actinium Pharmaceuticals in the first quarter worth $78,000. 27.50% of the stock is owned by institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.